AllCells

What AllCells does

AllCells is the cell and gene therapy (CGT) brand of Discovery Life Sciences, founded in 1998 and headquartered in Alameda, California. The company supplies human primary cells and tissue products—leukopaks, bone marrow, cord blood, whole blood, and isolated populations including CD34+ HSPCs, T cells, NK cells, B cells, monocytes, and PBMCs—to pharmaceutical and biotechnology companies, CDMOs/CROs, and academic/government researchers. Products are offered at both Research Use Only (RUO) and Good Manufacturing Practice (GMP) clinical-grade tiers, manufactured under FDA registration, 21 CFR Part 1271, 21 CFR Part 630, AABB, ISO 7 cleanroom, California Tissue Bank, and CLIA certifications, with EU Directive 2004/23/EC compliance enabling international positioning.

The underlying technology stack centers on apheresis collection using the Spectra Optia system, positive and negative immunomagnetic bead separation, controlled-rate cryopreservation with CryoStor CS10, and ISO 7 cleanroom processing. A proprietary Donor Management System (DMS) underpins a recallable donor database of thousands of qualified donors filterable by age, sex, BMI, HLA, race, ethnicity, and GMP eligibility, supporting industry-leading 98% RUO and 99% GMP collection deliverability rates, a 3-day standard lead time, and same-day delivery within the San Francisco Bay and Boston metropolitan areas from bi-coastal facilities in Alameda, CA and Quincy, MA.

Commercially, AllCells generates revenue through one-time product sales across the RUO and GMP product lines and through professional services including Custom Cell Isolation, Made-to-Order tissue products, Donor Management, and the Pre-Characterized Donor Selection Program. Distribution is hybrid: a self-service B2B webstore handles catalog and credit-card/blanket P.O. transactions, while a consultative enterprise field-sales motion—via a dedicated Customer Success Team, project managers, and donor management specialists—supports GMP, custom, and CDMO/CRO engagements. Cold-chain logistics are validated through AeroSafe Global and CryoPort for global shipping.

Name

AllCells

Legal name

AllCells

Website

https://allcells.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

51–100 employees

Short description

AllCells, the cell and gene therapy brand of Discovery Life Sciences (founded 1998), supplies human primary cells and tissue products—from RUO leukopaks and isolated cell populations to GMP clinical-grade starting materials—to pharmaceutical, biotech, CDMO/CRO, and academic customers developing cell and gene therapies.

Ownership category

akta.pro rank

Product category

Cell and Gene Therapy Starting Materials

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Blood and Organ Banks (621991), Medical Equipment and Supplies Manufacturing (3391)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

akta.pro secondary industries

Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA), Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Human primary cells
• Cell and gene therapy
• GMP leukopak products
• Apheresis collection services
• Donor management solutions

Headquarters

HQ city

Alameda

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. Research Use Only (RUO) Products: Sale of fresh and cryopreserved human primary cells and tissues for research applications including Leukopaks, Bone Marrow, Cord Blood, Whole Blood, and isolated cell products (CD34+ HSPCs, T Cells, NK Cells, Monocytes, B Cells, PBMCs). One-time product sales with per-unit pricing based on cell count and format.
2. GMP Clinical Grade Products: Sale of GMP-compliant clinical grade human primary cells for further manufacturing of allogeneic cell-based therapies. Includes GMP Fresh Leukopaks, GMP Cryopreserved Leukopaks, GMP Mobilized Leukopaks, GMP Bone Marrow, and GMP Cryopreserved PBMCs. Higher-value products with regulatory compliance documentation.
3. Custom Services: Custom Cell Isolation Services, Made-to-Order tissue products, Donor Management Services, and Pre-Characterized Donor Selection Program. Project-based professional services with custom specifications.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Core offering

AllCells manufactures and supplies fresh and cryopreserved human primary cells and tissue products (Leukopaks, Bone Marrow, Cord Blood, Whole Blood, and isolated cell populations including CD34+ HSPCs, T cells, NK cells, monocytes, B cells, and PBMCs) in both Research Use Only (RUO) and GMP clinical grades for cell and gene therapy research and manufacturing. The company also provides custom cell isolation, made-to-order tissue products, donor management services, and its Pre-Characterized Donor Selection Program to support pharmaceutical, biotechnology, CDMO/CRO, and academic customers from preclinical research through clinical manufacturing.

Product overview

AllCells is a provider of high-quality human primary cells and tissue products, operating as the Cell and Gene Therapy (CGT) brand of Discovery Life Sciences. The product portfolio spans Research Use Only (RUO) and GMP-grade offerings across four main categories: (1) Whole Tissue Products including Leukopaks (fresh, cryopreserved, guaranteed-cell-count, and mobilized variants), Bone Marrow, Cord Blood, and Whole Blood; (2) Isolated Cell Products including CD34+ HSPCs, T Cells, NK Cells, Monocytes, B Cells, and PBMCs; (3) GMP Clinical Products including GMP Fresh/Cryopreserved Leukopak, GMP Mobilized Leukopak, GMP Bone Marrow, and GMP Cryopreserved PBMCs; and (4) Services including Custom Cell Isolation, Made-to-Order products, Donor Management, and Pre-Characterized Donor Selection. The portfolio supports the cell and gene therapy development continuum from research through clinical commercialization, with same-day delivery in select US metro areas.

Differentiator

Problem solved

Functional benefit

Brands

• AllCells: CGT brand of Discovery Life Sciences specializing in high-quality human primary cells and whole tissue products for cell and gene therapy research and manufacturing.
• LeukoLab

Products and services

• AllCells RUO Products Research-use-only human primary cells and tissue products including Leukopaks, Mobilized Leukopaks, Bone Marrow, Cord Blood, and Whole Blood in fresh and cryopreserved formats, designed for drug discovery, preclinical testing, and process development for life sciences researchers and biomanufacturers.
• AllCells GMP Products Good Manufacturing Practice-grade clinical cell products for further manufacturing of allogeneic cell-based therapies, including GMP Fresh Leukopak, GMP Cryopreserved Leukopak, GMP Mobilized Leukopak, GMP Bone Marrow, and GMP Cryopreserved PBMCs, targeting pharmaceutical and biotechnology developers of cell and gene therapies.
• Leukopak Peripheral blood mononuclear cells collected via apheresis from healthy donors. Available in fresh and cryopreserved formats, with guaranteed cell counts (10B, 5B, 2.5B TNC) and unit sizes including Full Pak, Half Pak, and Quarter Pak for research and cell therapy development.
• Guaranteed-Cell-Count Leukopak Standardized leukopaks guaranteed to contain no less than 10 Billion, 5 Billion, or 2.5 Billion cells at release, eliminating donor variability challenges in experimental workflows for researchers and biomanufacturers.
• Mobilized Leukopak Leukopaks collected from donors treated with FDA-approved mobilization agents (G-CSF and/or Plerixafor) to increase CD34+ hematopoietic stem and progenitor cell yield. Available with various dosing regimens including Reg F (G-CSF), Reg H (G-CSF + Plerixafor), Reg A, and Reg B.
• Cryopreserved Leukopak Cryopreserved leukopaks offering workflow flexibility with high post-thaw recovery and viability using controlled rate freezer technology and CryoStor CS10 cryopreservation medium.
• Bone Marrow Fresh bone marrow aspirate collected from posterior iliac crest of healthy donors, available in 10mL, 25mL, 50mL, and 100mL sizes. Rich source of CD34+ hematopoietic stem and progenitor cells and mesenchymal stem cells for research applications.
• Cord Blood Umbilical cord blood CD34+ hematopoietic stem and progenitor cells, reported to be more naive with higher proliferative and engraftment potential than adult bone marrow-derived cells. Available as single or mixed donor products.
• Whole Blood Human whole blood collected by venipuncture containing red blood cells, white blood cells, plasma, and platelets. Available in various volumes and anticoagulant options including K2EDTA and NaHeparin.
• CD34+ HSPCs Hematopoietic stem and progenitor cells isolated from mobilized leukopaks, bone marrow, and cord blood via positive immunomagnetic bead separation. Critical for self-renewal and multilineage differentiation into mature blood cell types.
• T Cells Primary T cells isolated from leukopaks via immunomagnetic separation, available as CD3+ Pan T, CD4+ Helper T, CD8+ Cytotoxic T, regulatory T cells (Treg), and Gamma Delta T cells in various formats.
• NK Cells Natural killer cells isolated from leukopaks via positive or negative immunomagnetic bead separation. CD56+ NK cells are cytotoxic effectors of the innate immune system used in CAR-NK discovery research.
• Monocytes CD14+ monocytes isolated from leukopaks via immunomagnetic separation, available in positive and negative selection formats. Key modulators of inflammatory responses that can differentiate into macrophages and dendritic cells.
• B Cells CD19+ B cells isolated from leukopaks via immunomagnetic separation. Adaptive immune cells with roles in antibody production, antigen presentation, and immunomodulatory cytokine secretion.
• PBMCs Peripheral blood mononuclear cells isolated from leukopaks, consisting of T cells, B cells, NK cells, and monocytes. Available fresh and cryopreserved in various cell counts for immunology and disease modeling research.
• GMP Fresh Leukopak Clinical-grade fresh leukopak for further manufacturing of allogeneic cell-based therapies. Minimum 280mL volume, NLT 90% viability, NLT 26x10^6 cells/mL TNC concentration.
• GMP Cryopreserved Leukopak Clinical-grade cryopreserved leukopak manufactured in GMP ISO 7 cleanroom. Cryopreserved in CryoStor CS10 with NLT 2.5 billion cells per bag at NLT 90% pre-cryopreservation viability.
• GMP Mobilized Leukopak GMP-grade mobilized leukopak with dual mobilization regimen (G-CSF x5 days + Plerixafor x2 days). Enriched CD34+ cells for scalable and reproducible GMP manufacturing.
• GMP Fresh Bone Marrow Clinical-grade fresh whole bone marrow, rich source of CD34+ cells and mesenchymal stem cells. 100mL volume with NLT 8x10^6 cells/mL TNC concentration.
• GMP Cryopreserved PBMCs Industry-first ready-to-use GMP cryopreserved PBMC vials for allogeneic cell therapy manufacturing. End-to-end donor control with closed isolation system using Sepax C-Pro, available off-the-shelf or made-to-order.
• Custom Cell Isolation Services High-yield single-donor cell isolation services via immunomagnetic separation for CD34+ HSPCs, T cells, B cells, NK cells, and monocytes from leukapheresis material. Available as standard or sequential bulk isolations for cell therapy developers.
• Made-to-Order Tissue Products Custom tissue products engineered to meet specific project requirements including donor procurement, custom mobilization regimens, bulk isolations, cryopreservation needs, and specialized packaging.
• Donor Management Services End-to-end donor management solutions including recruitment, screening, monitoring, and retention of GMP-eligible donors with specific attributes for cell and gene therapy programs.
• Pre-Characterized Donor Selection Program Program enabling access to comprehensive donor characterization data including HLA typing, KIR profiling, and 9-color flow panel immunophenotyping for expedited donor selection for GMP collections.

Quantifiable outcome

• 98% collection deliverability rate (RUO)
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Market position

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/allcells_bio
• Facebookfacebook.com/allcells
• LinkedInlinkedin.com/company/allcells-llc

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AllCells